Views | |
---|---|
MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | 52 |
listopada 2021 | grudnia 2021 | stycznia 2022 | lutego 2022 | marca 2022 | kwietnia 2022 | maja 2022 | |
---|---|---|---|---|---|---|---|
MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial | 0 | 2 | 1 | 1 | 0 | 3 | 0 |
Views | |
---|---|
korkosz_et-al_mor103_a_human_monoclonal_antibody_2015.pdf | 64 |
korkosz_et-al_mor103_a_human_monoclonal_antibody_2015.odt | 2 |
Views | |
---|---|
United States | 29 |
Poland | 8 |
Germany | 3 |
Brazil | 1 |
China | 1 |
Views | |
---|---|
Ashburn | 20 |
Polska | 7 |
Des Moines | 2 |
Beijing | 1 |
Cambridge | 1 |
Fairfield | 1 |
Houston | 1 |
Krakow | 1 |
Woodbridge | 1 |